Technical Data Sheet

InVivoMAb anti-mouse CD39 (Entpd1)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**BE0479**
Clone:	**C39Mab-1**
Isotype:	Rat IgG2a, κ
Recommended Isotype Control(s):	InVivoMAb rat IgG2a isotype control, anti-trinitrophenol
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Immunogen:	LN229 cells over-expressing mouse CD39
Reported Applications:	Flow cytometry Western blot For details on *in vivo* applications, please contact technicalservice@bioxcell.com
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤1EU/mg (≤0.001EU/μg) Determined by LAL assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 μm filtered
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein G
RRID:	
Molecular Weight:	150 kDa

Description

The C39Mab-1 monoclonal antibody reacts with mouse CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (Entpd1), NTPDase-1, ATP-DPH, and Ecto-ATPase 1. The major function of CD39 is to hydrolyze extracellular adenosine triphosphate (eATP) to diphosphate (eADP) and adenosine monophosphate (AMP). 5'-nucleotidase (NT5E/CD73) dephosphorylates AMP to generate adenosine, which mediates an immunosuppressive tumor microenvironment in tumors. CD39 acts as an "immunological switch" by regulating the balance between immunostimulatory or pro-inflammatory eATP and immunosuppressive adenosine nucleotides, thereby controlling inflammation and immune responses. This function is critical in various processes, including immune cell regulation, anti-tumor immunity, and vascular inflammation. In various tumors, an increased expression of CD39 is shown to promote the local accumulation of adenosine surrounding tumors. Anti-CD39 monoclonal antibodies, as monotherapy or in combination with other targets, e.g., PD-1 blockade, for modulating the adenosine metabolism, are emerging as a promising immunotherapy strategy in cancer research.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out

of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/be0479?bxcs=9k1b3a#tab_references or scan the QR code below.

Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.
Not for resale.
Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC